All In Biotech

Drug Trial Radar · NCT04789356

Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity

Phase IV Study to Evaluate the Effectiveness of the Inactivated Adsorbed Vaccine Against COVID-19 CoronaVac, Among Public Safety and Education Workers With Risk Factors for Severity, in Manaus (Amazonas)

Last checked: Nov 20, 2026Latest source record: Jul 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

6,233

Actual

Start

Mar 18, 2021

Primary completion

Jul 5, 2021

Study completion Mar 2022

Sponsor

Lead sponsor
Fundação de Medicina Tropical Dr. Heitor Vieira DouradoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Butantan Institute
First posted
Mar 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a quasi-experimental study with risk-based allocation. Public security and education professionals from the state government will be included. In the initial evaluation, the presence of comorbidities associated with an increased risk of serious disease due to COVID-19 will be evaluated, according to the national plan for the implementation of vaccination against COVID-19. Those with at least one of these comorbidities will be invited to receive the study vaccine in two doses, with an interval of 28 days (±7 days). Participants with low risk (without comorbidities as a risk factor for severe COVID-19 according to the national plan for the implementation of vaccination against COVID-19) will not receive the vaccine within the scope of the research project. If, after 12 months, the participant in the low-risk group (no vaccine) has not received CoronaVac, or any other vaccine available, he/she will receive the vaccine, exactly as offered in the other group (two doses of CoronaVac with an interval of 28 days - with a tolerance of 7 days before or after). All participants will be followed up for 12 months from inclusion in the study. Immunization is expected to reduce the risk of moderate to severe disease of those with comorbidities to the level of those of the same age group who do not have these comorbidities but face similar occupational risks.

Conditions

  • Covid19

Interventions

  • Adsorbed SARS-CoV-2 (inactivated) vaccineBiological

    600 SU/dose; Two doses separated by 28 days (± 7 days). Intramuscular (deltoid) administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence density of moderate and severe clinical cases of COVID-19Time frame: 2 weeks after the second vaccine dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Escola Normal Superior - Universidade do Estado do Amazonas

    Manaus, Amazonas, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.